Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Novo Nordisk A/S — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.16 (market cap $12.87B), while Novo Nordisk A/S trades at $38.51 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 12.8× iShares JPMorgan USD Emerging Markets Bond ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 51 Days and Novo Nordisk A/S for 116 Days on average.
| EMB | NVO | |
|---|---|---|
Market Cap | $12.87B | $165.31B |
Volume | 14,946,002 | 11,432,838 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $63.98 |
52-Week Low | $90.14 | $35.29 |
Typical Hold Time | 51 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $91.13 with a slight 0.39% daily gain, though technical indicators signal bearish momentum with moving averages and ADX showing sell signals. The stock faces resistance near $91-92 levels while finding support around $90. Recent dividend announcements for H2-2026 provide income appeal, but fundamental metrics remain undisclosed in current data.
The outlook appears cautious given bearish technical signals and limited fundamental visibility. Investment opportunity rests on income generation through scheduled dividends, while risks include technical weakness and potential market volatility from rising bond yields affecting fixed-income alternatives.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
